JP2022512958A5 - - Google Patents
Info
- Publication number
- JP2022512958A5 JP2022512958A5 JP2021524959A JP2021524959A JP2022512958A5 JP 2022512958 A5 JP2022512958 A5 JP 2022512958A5 JP 2021524959 A JP2021524959 A JP 2021524959A JP 2021524959 A JP2021524959 A JP 2021524959A JP 2022512958 A5 JP2022512958 A5 JP 2022512958A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- nucleotide sequence
- hematopoietic
- cancer
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756683P | 2018-11-07 | 2018-11-07 | |
| US62/756,683 | 2018-11-07 | ||
| PCT/US2019/060287 WO2020097346A1 (en) | 2018-11-07 | 2019-11-07 | ANTI-GPC3 CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512958A JP2022512958A (ja) | 2022-02-07 |
| JP2022512958A5 true JP2022512958A5 (enExample) | 2022-11-11 |
Family
ID=70611157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524959A Pending JP2022512958A (ja) | 2018-11-07 | 2019-11-07 | トランス共刺激分子と組み合わされた抗ｇｐｃ３キメラ抗原受容体（ｃａｒ）及びその治療的用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220054545A1 (enExample) |
| EP (1) | EP3876950A4 (enExample) |
| JP (1) | JP2022512958A (enExample) |
| CN (1) | CN113260368B (enExample) |
| AU (1) | AU2019374828A1 (enExample) |
| CA (1) | CA3118889A1 (enExample) |
| WO (1) | WO2020097346A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3567049A4 (en) | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN110468105B (zh) * | 2018-05-09 | 2024-03-22 | 恺兴生命科技(上海)有限公司 | 表达il-18r结合蛋白的免疫效应细胞 |
| JP7456638B2 (ja) | 2018-08-14 | 2024-03-27 | ソティオ，リミティド ライアビリティ カンパニー | クレブス回路を調節するトランス代謝分子と組み合わせたキメラ抗原受容体ポリペプチド、及び、それらの治療的使用 |
| BR112022017512A2 (pt) * | 2020-03-26 | 2022-10-18 | Us Health | Receptores de antígeno quiméricos contendo domínio cd28h e métodos de uso dos mesmo |
| CN113754778A (zh) * | 2020-06-05 | 2021-12-07 | 上海交通大学 | 靶向cldn18.2的嵌合抗原受体及其用途 |
| CN114057890A (zh) * | 2020-07-31 | 2022-02-18 | 南京北恒生物科技有限公司 | 新型共刺激结构域及其用途 |
| CN112159818B (zh) * | 2020-08-20 | 2023-02-21 | 山东兴瑞生物科技有限公司 | 用于治疗hcc的核酸、其制备方法、具有该核酸的car-t细胞及细胞的制备方法 |
| WO2022068845A1 (en) * | 2020-09-29 | 2022-04-07 | Nanjing Legend Biotech Co., Ltd. | T cell and antigen-presenting cell engagers and uses thereof |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| CA3201652A1 (en) * | 2020-12-11 | 2022-06-16 | Xiaoping Bao | Human chimeric antigen receptor neutrophils, compositions, kits and methods of use |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| WO2022216811A2 (en) * | 2021-04-08 | 2022-10-13 | Artiva Biotherapeutics, Inc. | Chimeric antigen receptor comprising an anti-cd19 antibody or antigen-binding fragment thereof and natural killer cells comprising the same |
| WO2022236049A1 (en) * | 2021-05-07 | 2022-11-10 | Senti Biosciences, Inc. | Chimeric antigen receptors and methods of use |
| WO2023036043A1 (zh) * | 2021-09-09 | 2023-03-16 | 广东东阳光药业有限公司 | 抗癌结合分子及其应用 |
| AU2022388928A1 (en) | 2021-11-16 | 2024-05-16 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
| CN116426483B (zh) * | 2021-12-30 | 2024-02-23 | 南京紫珑生物科技有限公司 | Cd258蛋白在免疫治疗中的应用 |
| WO2024015995A2 (en) * | 2022-07-15 | 2024-01-18 | Albert Einstein College Of Medicine | Chimeric antigen receptors comprising a tmigd2 costimulatory domain and associated methods of using the same |
| CN117304343B (zh) * | 2023-10-11 | 2024-05-07 | 北京景达生物科技有限公司 | Gpc3靶向的car-nk细胞的制备及其应用 |
| CN117247466B (zh) * | 2023-11-20 | 2025-01-24 | 北京艺妙神州医药科技有限公司 | 抗磷脂酰肌醇蛋白聚糖3的嵌合抗原受体及其用途 |
| WO2025144887A1 (en) * | 2023-12-27 | 2025-07-03 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of il15 and light |
| WO2025191139A1 (en) * | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Conjugates of her2-specific antigen binding proteins and cytokines |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013070468A1 (en) * | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| CN104140974B (zh) * | 2013-05-08 | 2017-09-29 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| WO2015112626A1 (en) * | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| JP2017529851A (ja) * | 2014-09-26 | 2017-10-12 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター |
| JP7096667B2 (ja) * | 2015-07-01 | 2022-07-06 | 中外製薬株式会社 | Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤 |
-
2019
- 2019-11-07 AU AU2019374828A patent/AU2019374828A1/en not_active Abandoned
- 2019-11-07 JP JP2021524959A patent/JP2022512958A/ja active Pending
- 2019-11-07 CN CN201980087101.8A patent/CN113260368B/zh not_active Expired - Fee Related
- 2019-11-07 EP EP19882878.2A patent/EP3876950A4/en not_active Withdrawn
- 2019-11-07 CA CA3118889A patent/CA3118889A1/en active Pending
- 2019-11-07 WO PCT/US2019/060287 patent/WO2020097346A1/en not_active Ceased
- 2019-11-07 US US17/291,963 patent/US20220054545A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512958A5 (enExample) | ||
| US20230416339A1 (en) | Chimeric transmembrane proteins and uses thereof | |
| CN113260368B (zh) | 抗gpc3嵌合抗原受体(car)与反式共刺激分子的组合及其治疗用途 | |
| AU2017226269B2 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| RU2747733C1 (ru) | Терапевтические средства | |
| JP6813491B2 (ja) | サイトカイン融合タンパク質 | |
| EP3724320B1 (en) | Cell | |
| JP7723420B2 (ja) | Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤 | |
| US12570958B2 (en) | Single- and multi-chain chimeric antigen receptors | |
| KR102659440B1 (ko) | 키메라 폴리펩티드 및 그의 세포 막 내 국재화를 변경시키는 방법 | |
| JP7755597B2 (ja) | 細胞 | |
| KR20230061486A (ko) | 면역 세포 내 어댑터의 유도성 발현을 위한 시스템 | |
| JP2022537066A (ja) | キメラタンパク質を発現するｔ細胞 | |
| Wan | Département de Médecine | |
| WO2025191154A1 (en) | Therapeutic agents | |
| CN117120598A (zh) | 激活和增殖暴露于抗原的cd8 t细胞的方法、由此制备的具有增强的抗癌活性的cd8 t细胞及其用途 | |
| HK40102809A (zh) | T细胞调节性多聚体多肽及其使用方法 | |
| HK40109852A (zh) | T细胞调节性多聚体多肽及其使用方法 | |
| HK40102436A (zh) | T细胞调节性多聚体多肽及其使用方法 | |
| HK40102439A (zh) | T细胞调节性多聚体多肽及其使用方法 | |
| HK40046928A (en) | Chimeric transmembrane proteins and uses thereof |